Mtx (Methotrexate)

Methotrexate, the active ingredient in Mtx, is an antimetabolite presented as a sterile injectable solution for intramuscular, intravenous, and subcutaneous use. It is employed to treat autoimmune disorders and certain malignancies in adult and pediatric patients. GNH USA supplies Mtx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used across several disease families, primarily autoimmune and oncologic conditions. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell proliferation and improves plaque lesions. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Non‑Hodgkin lymphoma: inhibits tumor growth as part of combination chemotherapy. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring shortly after administration. - Fatigue: persistent tiredness that may affect daily activities. - Oral mucositis: painful sores or ulceration of the mouth lining. - Elevated liver enzymes: mild, transient increases in hepatic transaminases.

Serious or Rare Side Effects: - Severe hepatotoxicity: significant liver injury requiring monitoring or discontinuation. - Pulmonary fibrosis: progressive lung scarring presenting with cough and dyspnea. - Bone marrow suppression: marked decrease in blood cell counts leading to anemia, infection risk, or bleeding.

Methotrexate therapy requires careful monitoring and patient education. - Liver function monitoring: perform baseline and periodic liver enzyme tests. - Hematologic surveillance: regularly assess complete blood counts for signs of suppression. - Pregnancy avoidance: contraindicated in pregnancy due to teratogenic risk; use effective contraception. - Folic acid supplementation: co‑administer to reduce mucosal and hematologic toxicity. - Renal dose adjustment: modify dosing in patients with impaired renal clearance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Methotrexate interacts with several medicines, influencing efficacy and safety.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins and other β‑lactam antibiotics: may potentiate bone marrow suppression. - Sulfonamide antibiotics: elevate risk of severe hematologic effects. - Live vaccines: heightened risk of infection due to immunosuppression. - Azathioprine or other immunosuppressants: additive bone marrow depression.

Moderate Interactions (Monitor Closely): - Warfarin: methotrexate can enhance anticoagulant effect, requiring INR monitoring. - Oral contraceptives: may reduce contraceptive efficacy, necessitating backup methods. - Allopurinol: can increase methotrexate plasma levels, prompting dose review.